0RG8 Stock Chart & Stats
€163.70
-€1.90(-1.15%)
At close: 4:00 PM EDT
€163.70
-€1.90(-1.15%)
Day’s Range― - ―
52-Week Range€150.00 - €223.20
Previous CloseN/A
Volume97.94K
Average Volume (3M)57.59K
Market Cap
€18.69B
Enterprise Value€19.88K
Total Cash (Recent Filing)€203.90M
Total Debt (Recent Filing)€2.40B
Price to Earnings (P/E)65.1
Beta1.45
Next Earnings
Oct 22, 2026EPS Estimate
1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.02
Shares Outstanding97,330,410
10 Day Avg. Volume38,577
30 Day Avg. Volume57,592
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€233.33Price Target Upside42.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5
Revenue Forecast (FY)€3.13B
Bulls Say, Bears Say
Bulls Say
Recurring Bioprocess Consumables ModelRecurring consumables create repeat demand beyond initial equipment sales. As biopharma customers advance products into commercial manufacturing, validated single-use and filtration components can support durable revenue and customer retention.
Sharp Revenue RecoveryThe strong revenue rebound indicates recovering customer activity and bioprocess demand. Sustained growth in production volumes, facility expansions and drug-development progress could provide a durable foundation for further operating recovery.
Improved LeverageLower leverage and a larger equity base make the capital structure more balanced than in 2023. This improves financial flexibility for investment in bioprocess innovation and reduces balance-sheet pressure during industry recovery.
Bears Say
Margins Remain Below Prior PeaksRevenue recovery has not yet translated into normalized profitability. Margins remain well below earlier peaks, suggesting cost absorption, pricing or mix challenges could continue limiting earnings quality and the pace of recovery.
Weak Free Cash Flow ConversionImproving free cash flow is encouraging, but weak conversion from earnings signals that working capital and investment needs still absorb substantial cash. Persistent inconsistency could constrain deleveraging, shareholder returns and reinvestment capacity.
Sizable Debt And Modest ReturnsAlthough leverage has improved, the remaining debt load is material and current returns on equity are modest. If profitability does not normalize, debt servicing and underutilized capital could limit financial flexibility and long-term value creation.
Sartorius Stedim Biotech News
0RG8 FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest share price was €150.00 and its highest was €223.20 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €18.69B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Oct 22, 2026 which is in 55 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Jul 23, 2026. The company reported €1.25 earnings per share for the quarter, missing the consensus estimate of €1.263 by -€0.013.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech does not currently pay dividends.
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.19.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.25 in its last earnings report, missing expectations of €1.263. Following the earnings report the stock price went down -5.45%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in GB:0RG8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
0RG8 Stock 12 Month Forecast
Average Price Target
€233.33
▲(42.54% Upside)